Investigational New Drugs

, Volume 29, Issue 5, pp 786–799 | Cite as

5k, a novel β-O-demethyl-epipodophyllotoxin analogue, inhibits the proliferation of cancer cells in vitro and in vivo via the induction of G2 arrest and apoptosis

  • Danqing Xu
  • Ji Cao
  • Shijing Qian
  • Lin Li
  • Chunqi Hu
  • Qinjie Weng
  • Jianshu Lou
  • Difeng Zhu
  • Hong Zhu
  • Yongzhou Hu
  • Qiaojun He
  • Bo Yang


Etoposide (VP-16), a topoisomerase II (Topo II) inhibitor, has been widely used to treat malignancies. Its clinical application, however, has been hindered by the rise of acquired multidrug resistance (MDR). Here, we report that 4β-{[4-(pyrrolidin-1-ylmethyl)phenyl]amino}-4′-O-Demethyl-4-Epipodophyllotoxin (5k), a novel β-O-demethyl-epipodophyllotoxin analogue, possesses higher antitumor activity than its parent compound (VP-16) in a panel of various human tumor cell lines. More importantly, it was also effective against MDR cells both in vitro and in vivo. Using a KB/VCR MDR tumor xenograft model that overexpresses P-gp, 5k (2.5 mg/kg) exhibited a 2.4-fold higher growth inhibition rate versus VP-16 (5 mg/kg). In contrast, 5k and VP-16 displayed similar antitumor activities in a KB tumor xenograft model. Molecular and cellular mechanism studies revealed that 5k targeted Topo II by trapping DNA-Topo II cleavage complexes that could directly cause DNA damage. There were two distinct cellular responses to DNA damage elicited by the treatment with 5k: at low concentrations (20–80 nM), mitotic entry was arrested through the suppression of the activity of Cyclin B1/Cdc 2 complexes via the ATM/ATR signaling pathway; at high concentrations (1.25–5.00 μM), 5k-induced apoptotic signaling was mediated by the mitochondrial death pathways. Collectively, these data demonstrate the potential value of 5k as an antitumor drug candidate that should be further developed.


Topo II inhibitor MDR DNA damage G2 arrest Apoptosis 







5,5′6,6′-tetrachloro-1,1′3,3′-tetraethylbenzimidazol-carbocyanine iodide


mitochondrial membrane potential


multidrug resistance


DNA damage response

Topo II

Topoisomerase II




relative tumor volume


Ataxia-Telangiectasia Mutated


Ataxia-Telangiectasia and Rad3 related



Supplementary material

10637_2010_9423_Fig1_ESM.tif (9.1 mb)
High Resolution Image (TIFF 9273 kb)
10637_2010_9423_Fig2_ESM.tif (25 kb)
High Resolution Image (TIFF 24 kb)
10637_2010_9423_Fig3_ESM.tif (6.4 mb)
High Resolution Image (TIFF 6516 kb)


  1. 1.
    Bakshi R, Galande S, Muniyappa K (2001) Substrate specificity plays an important role in uncoupling the catalytic and scaffolding activities of rat testis DNA topoisomerase IIalpha. J Biomol Struct Dyn 18(5):749–760PubMedGoogle Scholar
  2. 2.
    Montecucco A, Biamonti G (2007) Cellular response to etoposide treatment. Cancer Lett 252(1):9–18PubMedCrossRefGoogle Scholar
  3. 3.
    Hande KR (1998) Etoposide: four decades of development of a topoisomerase II inhibitor. Eur J Cancer 34(10):1514–1521PubMedCrossRefGoogle Scholar
  4. 4.
    Meresse P, Dechaux E, Monneret C, Bertounesque E (2004) Etoposide: discovery and medicinal chemistry. Curr Med Chem 11(18):2443–2466PubMedGoogle Scholar
  5. 5.
    Hoeijmakers JH (2001) Genome maintenance mechanisms for preventing cancer. Nature 411(6835):366–374PubMedCrossRefGoogle Scholar
  6. 6.
    Kastan MB, Bartek J (2004) Cell-cycle checkpoints and cancer. Nature 432(7015):316–323PubMedCrossRefGoogle Scholar
  7. 7.
    Bartek J, Lukas J (2007) DNA damage checkpoints: from initiation to recovery or adaptation. Curr Opin Cell Biol 19(2):238–245PubMedCrossRefGoogle Scholar
  8. 8.
    Bartek J, Bartkova J, Lukas J (2007) DNA damage signalling guards against activated oncogenes and tumour progression. Oncogene 26(56):7773–7779PubMedCrossRefGoogle Scholar
  9. 9.
    Shiloh Y (2001) ATM and ATR: networking cellular responses to DNA damage. Curr Opin Genet Dev 11(1):71–77PubMedCrossRefGoogle Scholar
  10. 10.
    Pauklin S, Kristjuhan A, Maimets T, Jaks V (2005) ARF and ATM/ATR cooperate in p53-mediated apoptosis upon oncogenic stress. Biochem Biophys Res Commun 334(2):386–394PubMedCrossRefGoogle Scholar
  11. 11.
    Hutt AM, Kalf GF (1996) Inhibition of human DNA topoisomerase II by hydroquinone and p-benzoquinone, reactive metabolites of benzene. Environ Health Perspect 104(6):1265–1269PubMedCrossRefGoogle Scholar
  12. 12.
    Lindqvist A, van Zon W, Karlsson Rosenthal C, Wolthuis RM (2007) Cyclin B1-Cdk1 activation continues after centrosome separation to control mitotic progression. PLoS Biol 5(5):e123PubMedCrossRefGoogle Scholar
  13. 13.
    Rogakou EP, Pilch DR, Orr AH, Ivanova VS, Bonner WM (1998) DNA double-stranded breaks induce histone H2AX phosphorylation on serine 139. J Biol Chem 273(10):5858–5868PubMedCrossRefGoogle Scholar
  14. 14.
    Pines J (1999) Cell cycle. Checkpoint on the nuclear frontier. Nature 397(6715):172–175CrossRefGoogle Scholar
  15. 15.
    Sancar A, Lindsey-Boltz LA, Unsal-Kacmaz K, Linn S (2004) Molecular mechanisms of mammalian DNA repair and the DNA damage checkpoints. Annu Rev Biochem 73:39–85PubMedCrossRefGoogle Scholar
  16. 16.
    Wang XM, Li J, Feng XC, Wang Q, Guan DY, Shen ZH (2008) Involvement of the role of Chk1 in lithium-induced G2/M phase cell cycle arrest in hepatocellular carcinoma cells. J Cell Biochem 104(4):1181–1191PubMedCrossRefGoogle Scholar
  17. 17.
    Chen T, Wong YS (2008) Selenocystine induces apoptosis of A375 human melanoma cells by activating ROS-mediated mitochondrial pathway and p53 phosphorylation. Cell Mol Life Sci 65(17):2763–2775PubMedCrossRefGoogle Scholar
  18. 18.
    Ye J, Wang S, Leonard SS, Sun Y, Butterworth L, Antonini J, Ding M, Rojanasakul Y, Vallyathan V, Castranova V, Shi X (1999) Role of reactive oxygen species and p53 in chromium (VI)-induced apoptosis. J Biol Chem 274(49):34974–34980PubMedCrossRefGoogle Scholar
  19. 19.
    Xue L, Zhou B, Liu X, Qiu W, Jin Z, Yen Y (2003) Wild-type p53 regulates human ribonucleotide reductase by protein-protein interaction with p53R2 as well as hRRM2 subunits. Cancer Res 63(5):980–986PubMedGoogle Scholar
  20. 20.
    Yang Z, Wu D, Bui T, Ho RJ (2008) A novel human multidrug resistance gene MDR1 variant G571A (G191R) modulates cancer drug resistance and efflux transport. J Pharmacol Exp Ther 327(2):474–481PubMedCrossRefGoogle Scholar
  21. 21.
    Siegel RM (2006) Caspases at the crossroads of immune-cell life and death. Nat Rev Immunol 6(4):308–317PubMedCrossRefGoogle Scholar
  22. 22.
    Taylor BF, McNeely SC, Miller HL, Lehmann GM, McCabe MJ Jr, States JC (2006) p53 suppression of arsenite-induced mitotic catastrophe is mediated by p21CIP1/WAF1. J Pharmacol Exp Ther 318(1):142–151PubMedCrossRefGoogle Scholar
  23. 23.
    Smits VA, Klompmaker R, Vallenius T, Rijksen G, Mäkela TP, Medema RH (2000) p21 inhibits Thr161 phosphorylation of Cdc2 to enforce the G2 DNA damage checkpoint. J Biol Chem 275(39):30638–30643PubMedCrossRefGoogle Scholar
  24. 24.
    Yu J, Guo QL, You QD, Zhao L, Gu HY, Yang Y, Zhang HW, Tan Z, Wang X (2007) Gambogic acid-induced G2/M phase cell-cycle arrest via disturbing CDK7-mediated phosphorylation of CDC2/p34 in human gastric carcinoma BGC-823 cells. Carcinogenesis 28(3):632–638PubMedCrossRefGoogle Scholar
  25. 25.
    Norbury CJ, Zhivotovsky B (2004) DNA damage-induced apoptosis. Oncogene 23(16):2797–2808PubMedCrossRefGoogle Scholar
  26. 26.
    Ryan L, O’Callaghan YC, O’Brien NM (2005) The role of the mitochondria in apoptosis induced by 7beta-hydroxycholesterol and cholesterol-5beta, 6beta-epoxide. Br J Nutr 94(4):519–525PubMedCrossRefGoogle Scholar
  27. 27.
    Gaul L, Mandl-Weber S, Baumann P, Emmerich B, Schmidmaier R (2008) Bendamustine induces G2 cell cycle arrest and apoptosis in myeloma cells: the role of ATM-Chk2-Cdc25A and ATM-p53-p21-pathways. J Cancer Res Clin Oncol 134(2):245–253PubMedCrossRefGoogle Scholar
  28. 28.
    Clifford B, Beljin M, Stark GR, Taylor WR (2003) G2 arrest in response to topoisomerase II inhibitors: the role of p53. Cancer Res 63(14):4074–4081PubMedGoogle Scholar
  29. 29.
    Siu WY, Lau A, Arooz T, Chow JP, Ho HT, Poon RY (2004) Topoisomerase poisons differentially activate DNA damage checkpoints through ataxia-telangiectasia mutated-dependent and -independent mechanisms. Mol Cancer Ther 3(5):621–632PubMedGoogle Scholar

Copyright information

© Springer Science+Business Media, LLC 2010

Authors and Affiliations

  • Danqing Xu
    • 1
  • Ji Cao
    • 1
  • Shijing Qian
    • 1
  • Lin Li
    • 1
  • Chunqi Hu
    • 2
  • Qinjie Weng
    • 1
  • Jianshu Lou
    • 1
  • Difeng Zhu
    • 1
  • Hong Zhu
    • 1
  • Yongzhou Hu
    • 2
  • Qiaojun He
    • 1
  • Bo Yang
    • 1
  1. 1.Institute of Pharmacology & Toxicology, College of Pharmaceutical SciencesZhejiang UniversityHangzhouPeople’s Republic of China
  2. 2.Zhejiang University-Ecole Normole Superienre Joint Laboratory Medicinal ChemistryZhejiang UniversityHangzhouPeople’s Republic of China

Personalised recommendations